Why is the price of the generic drug enasidenib so different?

Ensidipine (enasidenib)Approved for marketing by Nikkei USFDA , jointly developed by Celgene and Agios Pharmaceutical Company, for the treatment of isocitrate dehydrogenase 2 detected by FDA approved tests (IDH2)Adult patients with relapsed or refractory acute myeloid leukemia(AML)mutations.

Currently, the only generic drugs that are officially on the market are produced by Bangladesh’s Ziska Pharmaceuticals and Everest Pharmaceuticals. The retail price of Ziska Pharmaceuticals in Bangladesh50mg60tablets4 is about one thousand yuan, and the retail price of Everest Pharmaceuticals in Bangladesh is50mg30pills5about one thousand yuan. The price difference between Ziska Pharmaceuticals and Everest Pharmaceuticals is relatively large. This does not mean that there is a difference in the quality of the drugs, but that it is due to different pricing by the pharmaceutical companies. Ziskar Pharmaceuticals is a large pharmaceutical company in Bangladesh that has been in existence for 35 years. It has strict control over its production lines, so there will be no gap between the products produced by the two manufacturers, and patients can use it with confidence.

Ensidipineis a small molecule inhibitor of isocitrate dehydrogenase2 (IDH2)enzyme. In vitro, ensidipinetargets mutantIDH2mutants at approximately 40fold lower concentrations than the wild-type enzyme. BodyR140Q, R172S and R172K. In the IDH2mutatedAML mouse xenograft model, ensidipine inhibits mutation AlteredIDH2enzyme results in reduced 2-hydroxyglutarate(2-HG) levels and induces myeloid differentiation in vitro and in vivo. In blood samples from IDH2 mutated AML patients, ensidipineReduced 2-HG levels, decreased blast cell counts, and increased the percentage of mature myeloid cells. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.